Company intelligence / Profile preview
CSL Limited
Melbourne, Victoria, Australiacsl.com ↗
- Ownership
- Public · CSL
- Employees
- ~32000
- Development stage
- Commercial
01
Overview
CSL is a global leader in biotherapeutics with over a century of history. It has more than 580 clinical trials conducted or ongoing worldwide. Recent clinical milestones include regulatory approvals for new therapies such as garadacimab for hereditary angioedema in Switzerland and the sa-mRNA COVID vaccine Kostaive in Japan. The company maintains strong commercial performance with $22+ billion revenue in FY2024.
- Therapeutic areas
- Infectious DiseasesImmunologyNephrologyHematology
- Modalities
- Plasma-derived therapiesRecombinant proteinsVaccines (egg-based, cell-based, mRNA, adjuvanted)Gene therapyCell therapy
- Industry
- Pharma
02
Drug pipeline
40 assets39 more assets in the full pipeline.
03
Partnerships
AstraZeneca – manufacturing partnership on COVID‑19 vaccinesThe University of Queensland – research collaboration on vaccines
Beyond the preview
Go deeper on CSL Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSL Limited.